Is tacrolimus associated with lymphoma
Reading File
Searching PubMed
tacrolimus lymphoma risk
Finding Sources
Reading Article
PMID: 34390192
Reading File
Reading File
I have enough material for a thorough answer. Here is the full synthesis:
Tacrolimus and Lymphoma Risk
Yes - tacrolimus is associated with an increased risk of lymphoma, through both systemic and topical formulations, though the mechanisms and magnitude of risk differ.
Mechanism
Tacrolimus binds to the immunophilin FKBP-12, and the complex inhibits calcineurin, blocking IL-2 transcription and T-cell activation. This immunosuppression impairs immune surveillance - particularly against Epstein-Barr virus (EBV), which can drive unchecked B-cell proliferation. The result is a predisposition to post-transplant lymphoproliferative disorder (PTLD) and non-Hodgkin lymphoma (NHL) specifically.
Systemic Tacrolimus (Transplant Recipients)
In organ transplant patients, systemic tacrolimus carries a well-established malignancy risk. As documented in Goldman-Cecil Medicine:
"Like cyclosporine, tacrolimus... is associated with an increased risk of infections, lymphoma, and skin cancers."
- Goldman-Cecil Medicine, p. 290
The risk is shared with cyclosporine (also a calcineurin inhibitor), though tacrolimus may carry a comparatively lower skin cancer risk than cyclosporine (due to different effects on keratinocyte pathways - Fitzpatrick's Dermatology, p. 3555).
Topical Tacrolimus (Atopic Dermatitis)
The FDA has issued a black box warning for topical tacrolimus noting that new malignancies - including skin cancers and lymphoma - have been reported. However, the risk with topical formulations is considered theoretical/small compared to systemic use:
"Currently, there is an FDA-issued boxed warning for topical tacrolimus that outlines a lack of long-term safety data and that new malignancies (eg, skin cancer and lymphoma) have been reported."
- Fitzpatrick's Dermatology, p. 3554
A 2021 systematic review and meta-analysis (Wu et al., PMID 34390192) quantified this risk:
- Topical tacrolimus: RR 1.68 (95% CI 1.39-2.04) for overall lymphoma
- Non-Hodgkin lymphoma specifically: RR 1.89 (95% CI 1.53-2.32)
- Hodgkin lymphoma: no significant increased risk
- Absolute incidence remained low (0.02-0.09% in TCI users vs. 0.02-0.06% in controls)
Summary Table
| Setting | Formulation | Lymphoma Risk | Type |
|---|---|---|---|
| Organ transplant | Systemic | Well established | PTLD, NHL |
| Atopic dermatitis | Topical | Statistically significant but small in absolute terms | NHL primarily |
| Hodgkin lymphoma | Either | Not significantly increased | - |
Clinical Implications
- Transplant patients should be monitored for PTLD, especially EBV-seronegative recipients receiving EBV-positive organs
- Topical tacrolimus should be used at the lowest effective dose, restricted to small skin areas, and is labeled as a second-line agent after topical steroids have failed
- Application under occlusion should be avoided to limit systemic absorption
- Topical tacrolimus is contraindicated on premalignant skin lesions
This is a shared conversation. Sign in to Orris to start your own chat.